A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV

Related documents

• Protective factors for adolescent sexual risk behaviours and experiences linked to HIV infection in South Africa: a three-wave longitudinal analysis of caregiving, education, food security, and social protection#638161
• The Transdermal Permeability of Terpenoids as an Insect Repellent#638163
• BTEX Concentration and Risk Assessment from Biological Activated Sludge in Municipal Wastewater Treatment Plants: Systematic Review#638165
• Predictors of TB disease in HIV-exposed children from Southern Africa#638166
• The developmental status of pre-term infants on discharge from a private neonatal intensive care unit in Johannesburg#638168